News Release

RIBOMIC Announces Initiation of RAMEN Open-Label Extension Clinical Trial for RBM-007 in wet AMD Patients

TOKYO, November 11, 2020 - RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TYO:4591), today announced that the first subject was dosed in an open-label extension trial - named 'RAMEN Study' for wet AMD. The study design allows eligible subjects who have completed the ongoing phase 2 double-masked TOFU Study to receive additional four monthly treatments of RBM-007. RAMEN is designed to provide long-term safety and efficacy feedback for the original trial outcomes as well as evaluate additional treatment effects.

"This is an important milestone for the company. Acceptable safety performance of our ongoing TOFU study allows us to submit the RAMEN Study protocol with the FDA. The trial extension is important since additional doses and treatment times will allow us to further evaluate structural changes in fibrosis. With positive functional and anatomical changes resulting from FGF2 suppression in TOFU and RAMEN studies, the results would not only contribute further to our pivotal phase development strategy, but would also establish that structural measures of fibrosis might be promising biomarkers to assess/predict progression of wet AMD in regards to the pathogenesis of the disease. Furthermore, anti-fibrotic improvements would help patients considerably, while differentiating RBM-007 from current wet AMD drugs by preventing the damages that cause vision loss in the first place," said Yoshikazu Nakamura, CEO of RIBOMIC Inc. "Our principal investigators in the TOFU study sites are excited about participating in this extension study to evaluate the potential of the drug. We plan to complete both studies by the end of 2021. We believe that the combined data from TOFU (double-masked study using Eylea as comparator) and RAMEN (open-label extension study to assess long-term effect of RBM-007), will provide strong evidence of the importance of RBM-007 for patients, retina specialists and healthcare providers."

The RAMEN Study is being conducted at the same sites in U.S. as the TOFU Study. Trial details will become available soon at clinicaltrials.gov.

About RBM-007 and development background

RBM-007 is a novel oligonucleotide-based aptamer with potent anti-FGF2 (fibroblast growth factor 2) activity. Currently approved therapies for wet AMD, intravitreal injections of anti-VEGF drugs, have shown dramatic visual benefits for wet AMD patients. However, a significant portion of wet AMD patients exhibit incomplete response to therapy, and over the extended management course can lose vision, with the formation of submacular fibrosis as one risk factor. RIBOMIC investigated a novel therapy for wet AMD targeting fibroblast growth factor 2 (FGF2), which is implicated in not only angiogenesis but also fibrosis in several diseases, and created RBM-007, a novel oligonucleotide-based aptamer with potent anti-FGF2 activity. RBM-007 is chemically synthesized, and pharmacokinetic studies of RBM-007 in the rabbit vitreous revealed high and

relatively long-lasting profiles, which are superior to the other approved anti-VEGF drugs. The dual action of RBM-007 (anti-angiogenic and anti-scarring) holds promise as an additive or alternative therapy to anti-VEGF treatments for wet AMD.

About RAMEN study

A Multi-Center, Open Label, TOFU Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects with Wet Age-related Macular Degeneration (RAMEN study) is a multi-center, open label, extension study assessing the efficacy and safety of additional intravitreal injections of RBM-007 in subjects with wet AMD.

Study Design	Multi-center, open-label study
Patient Population	Subjects who have completed all visits in TOFU Study and meet eligibility criteria
Administration	Four monthly intravitreal injections of RBM-007
Primary Endpoints	Mean change in Best Corrected Visual Acuity from Baseline and safety
Key Secondary Endpoints	Change from Baseline in characteristics of fibrosis Change from Baseline in central subfield thickness (CST) and macular volume
Study Arms	RBM-007 (2.0 mg)
Number of Subject	40
Duration	5 months (primary endpoint at month 1 after last injection)
Location	Around 10 sites across the United States

See ClinicalTrials.gov for TOFU study
https://clinicaltrials.gov/ct2/show/NCT04200248

About wet Age-related Macular Degeneration

Wet (exudative) age-related macular degeneration, is the leading cause of blindness in the United States and Europe. It is caused by the formation of abnormal and leaky new blood vessels under the retina, termed choroidal neovascularization. The leakage of fluid from the vessels causes retinal thickening and retinal degeneration including fibrotic scar formation, and leads to severe and rapid loss of vision.

ABOUT RIBOMIC

RIBOMIC is a bio-venture company centered on drug discovery. The company is engaged in the field of aptamer therapeutics, which is one type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company's core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs that target the broad field of unmet medical needs, which encompasses eye disorders, pain and many other problems.
See RIBOMIC website for more information.
https://www.ribomic.com/eng/

Forward-Looking Statements
This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties.
Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Contacts for inquiries or additional information:
RIBOMIC Inc.
Corporate Planning Department
ir.inquiry@ribomic.com